Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
04:06pm, Thursday, 15'th May 2025
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 01'st May 2025
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
Solid Biosciences to Participate at The Citizens Life Sciences Conference
08:00am, Wednesday, 30'th Apr 2025
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neur
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting
08:00am, Tuesday, 29'th Apr 2025
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, wil
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
04:50pm, Tuesday, 08'th Apr 2025
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly im
Can Solid Biosciences Challenge Sarepta in the DMD Market?
07:31am, Tuesday, 08'th Apr 2025
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 01'st Apr 2025
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
02:25pm, Monday, 31'st Mar 2025
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
08:00am, Wednesday, 12'th Mar 2025
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, wil
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
10:55am, Friday, 07'th Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable,
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
10:16am, Friday, 07'th Mar 2025
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
04:16pm, Thursday, 06'th Mar 2025
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administ
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Wednesday, 05'th Mar 2025
CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neur
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:07pm, Tuesday, 04'th Mar 2025
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
08:48am, Wednesday, 19'th Feb 2025
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
